Stocks · News reference
INVO Fertility Says Wisconsin Fertility Institute Presented Five Retrospective Platelet-Rich Plasma Study Abstracts At Midwest Reproductive Symposium International On July 26-29
AGE AND OVARIAN RESERVE INFLUENCE RESPONSE TO OVARIAN PLATELET-RICH PLASMA IN IVF CYCLESKEY FINDINGS AND CONCLUSIONS: Among 19 patients, those younger than 35 years (n = 3) demonstrated the most robust improvements in
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
INVO Fertility Announces Partnership with PatientFi for Patient Financing
INVO Fertility, Inc. has partnered with PatientFi to provide patients at its clinics with new monthly payment plan options for fertility treatments.
8-K filing — INVO Fertility, Inc. (IVF)
Filed: 2026-11-04 AccNo: 0001493152-26-049991 Size: 1 MB Item 5.03: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year Item 8.01: Other Events Item 9.01: Financial Statements and Exhibits
Trading Halt: Halt status updated at 8:55:00 AM ET: Quotation Resumption: News and Resumption Times
INVO Fertility Announces 1-for-4 Reverse Stock Split
INVO Fertility, Inc. has announced a 1-for-4 reverse stock split of its common stock, effective October 30, 2026.
INVO Fertility Announces a 1:4 Reverse Stock Split Effective Pre-Market Opening on October 30, 2026
INVO Fertility announced a 1-for-4 reverse stock split effective October 30, 2026, under the same ticker symbol 'IVF' on Nasdaq Capital Market. Post-split, the company will have approximately 1,192,841 shares outstanding and 62,500,000 authorized shares. The company operates four fertility clinics in the U.S. and distributes its proprietary INVOcell technology to third-party clinics.